Epix cuts jobs as FDA request for more Vasovist data means a year's delay
This article was originally published in Clinica
Executive Summary
The US approval of Epix Pharmaceuticals' blood-pool contrast agent, Vasovist, could be delayed by a further year after the FDA issued the firm with another "approvable" letter requesting more data. Following the announcement, Epix said it would be making "substantial" cuts to its workforce and research plans in a bid to refocus its resources.